Trump FDA overhauls COVID-19 vaccine approval to focus on older populations, high-risk individuals
The Food and Drug Administration is shifting its annual COVID-19 vaccine approval policies to focus on Americans older than age 65 and other "high-risk" individuals, while increasing the standard of evidence to approve COVID vaccines for low-risk individuals.
"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at low risk," FDA's Center for Biologics Evaluation and Research chief, Vinay Prasad, and FDA Commissioner Martin Makary, wrote in the New England Journal of Medicine Tuesday. "These clinical trials will inform future directions for the FDA, but more important, they will provide information that is desperately craved by health care providers and the American people."
Americans over the age of 65 and those considered at high-risk of contracting the virus will be able to receive an annual COVID-19 vaccine this fall, the essay outlined, while vaccines for low-risk Americans will likely face stricter scientific analysis before they are made available to the public. The FDA estimated that about "100 million to 200 million Americans" older than age 65 or considered at high-risk will still have access to vaccines.
Prasad and Makary said in their essay that the U.S. will move away from a "one-size-fits-all" paradigm that promoted COVID-19 vaccines for the vast majority of Americans, stretching from children to the elderly. The shift, they said, will bring America's policies more in line with guidelines in European nations.
"While all other high-income nations confine vaccine recommendations to older adults (typically those older than 65 years of age), or those at high risk for severe Covid-19, the United States has adopted a one-size-fits-all regulatory framework and has granted broad marketing authorization to all Americans over the age of 6 months," the health leaders wrote in the New England Journal.
"The U.S. policy has sometimes been justified by arguing that the American people are not sophisticated enough to understand age- and risk-based recommendations," they wrote. "We reject this view."
The FDA's policy shift will include requiring vaccine manufacturers to gather clinical trial data to justify rolling out new COVID-19 vaccines for Americans at low risk of contracting the virus.
Prasad and Makary held a roundtable discussion on the framework outlined in their medical essay Tuesday afternoon to walk Americans through the policy shift. Prasad explained that health officials under the Trump administration are taking into account that Americans have balked at the FDA's guidance under the Biden administration to receive multiple booster shots, while other Americans demand access to the vaccines.
"We have to admit to ourselves that America is deeply divided on the policy issue of repeat COVID 19 vaccine doses or boosters," he said. "There are some Americans out there who are worried that the FDA has not fully documented and interrogated the safety harms of these products, and they are categorically opposed to these products. There are also some Americans we also have to recognize, who are desperate for additional protection, and they demand these products. But the truth is that most doctors and most of the public are entirely uncertain, and that is reflected in low vaccine uptake of these products."
The pair added during the roundtable that Americans' trust in the scientific community has cratered since the pandemic.
"Survey after survey shows trust in institutions like the FDA and scientists in general, it's rock bottom," Prasad said during the roundtable. "I mean, we have lower trust than Congress, and that's saying something, you know. And we need to rebuild that trust. And part of rebuilding that trust is having conversations like this, writing articles like we've done in the New England Journal, and having a common-sense evidence-based framework for rebuilding that trust."
The pair cited in their article in the New England Journal that "public trust in vaccination in general has declined," including for "vital immunization programs such as that for measles–mumps–rubella (MMR) vaccination, which has been clearly established as safe and highly effective."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
25 minutes ago
- Fox News
NEWT GINGRICH: Pay less, know more — Trump is slashing red tape and lowering your healthcare costs
One of the boldest and most consistent themes in President Donald J. Trump's healthcare agenda is his determination to reduce the role and power of middlemen. From insurance companies to pharmacy benefit managers (PBMs) – and even hospitals –these intermediaries profit from the inefficiencies of our bloated health system. The result is higher costs for American families. As I explain in my new book, "Trump's Triumph: America's Greatest Comeback," the U.S. healthcare system isn't expensive just because care is costly. It's expensive because the system is complex – by design. The third-party payment structure, whether public or private, adds layers of bureaucracy. This opens the door for middlemen to offer supposed solutions that serve their own bottom lines – not patients. It's a vicious cycle: more rules lead to more middlemen, which lead to even more rules, red tape, and rising costs. President Trump understood this – and he took action. In his first term, he issued a groundbreaking executive order on price transparency. For the first time, hospitals were required to disclose the real cost of procedures, enabling patients to compare prices before receiving care. While the Biden administration weakened enforcement, Trump doubled down in his second term with an even stronger push for what he called "radical transparency." Radical transparency is the antidote to healthcare's worst inefficiencies. When patients and employers can see wide price differences for the same procedures – even within the same hospital system – the games played behind the scenes get exposed. These inflated prices often have little to do with quality and everything to do with how well insurers negotiate – or how many middlemen take a cut. The same is true for prescription drugs. PBMs – giant corporations that control which drugs are covered and at what cost – use their market power to inflate prices. Three PBMs control 80 percent of the market. They're often subsidiaries of major insurers, forming vertically integrated monopolies. New data from the Pacific Research Institute shows that most PBMs skim more money off high-cost prescriptions than European countries charge. It's no wonder Americans are paying more. Hospitals play a role as well. Many exploit a well-intentioned federal program known as 340B, which allows them to purchase drugs at steep discounts. Instead of passing the savings to patients, they bill insurers full price and pocket the difference. The program was meant to expand care for low-income patients, but there's little oversight to ensure this happens. President Trump's recent executive order on drug pricing targets this broken system. By creating a pathway for manufacturers to sell directly to patients, health plans, pharmacies, and clinics – without the markup – he's offering a way to bypass the middlemen. This isn't theory – it's already working. When insulin makers launched direct-to-consumer programs, they sold the same drug at one-fourth the price patients were paying through insurance – while still making a profit. That's the power of real market competition – without a single government price control. This stands in sharp contrast to the Left's top-down vision. Whether it's price controls, centralized purchasing, or government-run insurance, the left's answer is always more bureaucracy. But more bureaucracy means more complexity – and more room for middlemen to thrive. Perhaps the most visionary part of President Trump's health care agenda is his call to Make America Healthy Again. For decades, we've operated a "sick care" system focused on treating illness after it strikes. Trump's approach is different. It emphasizes prevention, lifestyle, and personal responsibility – turning Americans from passive recipients into active participants in their own health. In this model, the government's role isn't to run the system but to create an environment in which patients and doctors can lead – with access to better tools, more transparency, and useful information. That means clearer labeling for ultra-processed foods, ensuring gold standard scientific data free of conflicts of interest, and addressing environmental factors that contribute to chronic disease. These kinds of structural reforms empower people to make informed choices and live healthier lives – without mandates or micromanagement. It's a model that eliminates the ultimate middleman: the system itself. President Trump's leadership has laid the groundwork for a transparent, patient-centered, free-market healthcare system. But the job isn't done. Congress should join him in continuing this fight – not just to lower costs, but to restore power to the American people. America deserves a healthcare system that benefits Americans – not industry middlemen.
Washington Post
29 minutes ago
- Washington Post
Top CDC covid vaccine adviser quits after RFK Jr. ended recommendations
A top coronavirus vaccine adviser at the Centers for Disease Control and Prevention has resigned, citing concerns that she could no longer help vulnerable people after federal health officials rescinded long-standing recommendations to immunize children and pregnant women. Lakshmi Panagiotakopoulos said in an email to colleagues Tuesday that she made a 'personal decision' to quit the CDC after 12 years.
CBS News
30 minutes ago
- CBS News
Man charged in Palm Springs fertility clinic bombing after being arrested by FBI at New York's JFK airport
A man was charged Wednesday in connection with last month's bombing outside a fertility clinic in Palm Springs, California, after being apprehended in Europe and flown to New York City, where he was he was arrested overnight, authorities said. Daniel Park, 32, of Washington state is charged with providing and attempting to provide material support to a terrorist, U.S. Attorney Bilal Essayli announced during a news conference. Park is accused of shipping approximately 180 pounds of ammonium nitrate — commonly used as a precursor to construct homemade explosives — to the bomber, who was identified by officials as 25-year-old Guy Bartkus. Bartkus died in the blast outside the American Reproductive Centers fertility clinic on May 17. Four other people were injured in the explosion. Essayli said evidence shows Park and Bartkus shared extremist beliefs. According to the criminal complaint filed Wednesday, "Bartkus's attack was motivated by his pro-mortalism, anti-natalism, and anti-pro-life ideology, which is the belief that individuals should not be born without their consent and that non-existence is best." Investigators said Park also paid for an additional 90 pounds of ammonium nitrate that was shipped to Bartkus in the days leading up to the bombing. Park spent approximately two weeks visiting Bartkus' residence in Twentynine Palms, California, in late January and early February and ran "experiments" in his garage, Essayli said. FBI Assistant Director Akil Davis, in charge of the bureau's Los Angeles field office, said Park was charged because of his contributions to the bomb. "Park was in possession of an explosive recipe that was similar to the Oklahoma City bombing," Davis told reporters, referring to the 1995 attack on the Alfred P. Murrah Federal Building in downtown Oklahoma City that killed 168 people. "We believe that Park had knowledge of how to create an ANFO bomb, ammonium-nitrate-fuel-oil bomb." The FBI and other law enforcement personnel gather evidence a day after a bomb exploded near a reproductive health facility in Palm Springs, California, May 18, 2025. Reuters/David Swanson Park flew to Warsaw, Poland, on May 21, a few days after the bombing, Davis said. Polish authorities detained Park at the request of U.S. officials on Friday. He was flown back to the U.S. and taken into custody by American authorities at New York's John F. Kennedy International Airport overnight. Park is scheduled to appear in federal court in Brooklyn, New York, Wednesday afternoon. He is expected to be prosecuted in Los Angeles. Four Polish border guards were with Park when he was taken back to the U.S., and two members of the FBI flying squad were also on the flight, according to two senior U.S. officials with direct knowledge of the investigation. Park consented to speak with the FBI at JFK and was interviewed by them there. Police in Palm Springs said the bomber backed his Ford Fusion into a parking spot outside the clinic before the powerful explosion left a crater on the morning of May 17. The explosion could be felt more than a mile away from the blast zone, the FBI said. The vehicle exploded outside American Reproductive Centers, a fertility clinic with a full-service IVF lab that dd not perform abortions. The blast caused significant damage to the building. The facility also lost power, but it was restored in time so no embryos were lost in the attack. The clinic reopened about two weeks later at a new location. The FBI believed that the bombing was premeditated and called the attack an "intentional act of terrorism." Detectives said they believed Bartkus acted alone at the site of the attack, but said they were scouring his online chats to learn whether anyone helped him buy parts or refine the design of the bomb. Investigators said the blast pattern shows that the device was far more damaging than a low-grade explosive such as fireworks. The FBI said Bartkus had access to a large quantity of commercially available chemical products that could be combined to create a homemade explosive device. Twentynine Palms is home to a large Marine Corps base about an hour's drive from Palm Springs. contributed to this report.
